相似文献
1
Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies.
Curr Neuropharmacol. 2009 Dec;7(4):337-42. doi: 10.2174/157015909790031166.
2
Treatment of immune-mediated, dysimmune neuropathies.
Acta Neurol Scand. 2005 Aug;112(2):115-25. doi: 10.1111/j.1600-0404.2005.00448.x.
3
Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies.
J Neuroimmunol. 2011 Feb;231(1-2):61-9. doi: 10.1016/j.jneuroim.2010.09.015. Epub 2010 Nov 5.
4
Overview of the pathogenesis and treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulins.
Biologics. 2010 Mar 24;4:45-9. doi: 10.2147/btt.s4881.
5
Expression of chemokine receptors on peripheral blood mononuclear cells of patients with immune-mediated neuropathies treated with intravenous immunoglobulins.
Eur J Neurol. 2006 Dec;13(12):1359-63. doi: 10.1111/j.1468-1331.2006.01521.x.
6
Immune mediated neuropathies--an update on therapeutic strategies.
J Neurol. 2004 Feb;251(2):127-37. doi: 10.1007/s00415-004-0323-5.
7
Treatment of immune neuropathies.
Curr Opin Neurol. 2002 Oct;15(5):623-31. doi: 10.1097/00019052-200210000-00014.
8
Systematic reviews of treatment for inflammatory demyelinating neuropathy.
J Anat. 2002 Apr;200(4):331-9. doi: 10.1046/j.1469-7580.2002.00041.x.
9
Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review.
Curr Drug Saf. 2019;14(1):3-13. doi: 10.2174/1574886313666181017121139.
10
[Autoimmune neuropathies: diagnosis, treatment, and recent topics].
Brain Nerve. 2011 Jun;63(6):549-55.
引用本文的文献
1
Comparison of intravenous immunoglobulin and plasma exchange in hospital-acquired infections of autoimmune encephalitis in a tertiary care center.
Asian Biomed (Res Rev News). 2025 Jul 28;19(3):147-153. doi: 10.2478/abm-2025-0018. eCollection 2025 Jun.
2
A pathologically expanded, clonal lineage of IL-21-producing CD4+ T cells drives inflammatory neuropathy.
J Clin Invest. 2024 Jun 11;134(15):e178602. doi: 10.1172/JCI178602.
3
HLA dependency and possible clinical relevance of intrathecally synthesized anti-IgLON5 IgG4 in anti-IgLON5 disease.
Front Immunol. 2024 May 16;15:1376456. doi: 10.3389/fimmu.2024.1376456. eCollection 2024.
4
A pathologically expanded, clonal lineage of IL-21 producing CD4+ T cells drives Inflammatory neuropathy.
bioRxiv. 2024 Jan 8:2024.01.07.574553. doi: 10.1101/2024.01.07.574553.
5
Immune-Mediated Neuropathies: Pathophysiology and Management.
Int J Mol Sci. 2023 Apr 14;24(8):7288. doi: 10.3390/ijms24087288.
6
The Cumulative Detrimental Effect of COVID-19 Pneumonia in a Patient with Myasthenic Crisis: A Case Report and Overview of the Literature.
Life (Basel). 2022 Sep 23;12(10):1482. doi: 10.3390/life12101482.
7
Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome.
Neurotherapeutics. 2022 Apr;19(3):885-896. doi: 10.1007/s13311-022-01253-4. Epub 2022 Jun 1.
8
Pharmacotherapy of Generalized Myasthenia Gravis with Special Emphasis on Newer Biologicals.
Drugs. 2022 Jun;82(8):865-887. doi: 10.1007/s40265-022-01726-y. Epub 2022 May 31.
9
IgG4 Autoantibodies in Organ-Specific Autoimmunopathies: Reviewing Class Switching, Antibody-Producing Cells, and Specific Immunotherapies.
Front Immunol. 2022 Mar 24;13:834342. doi: 10.3389/fimmu.2022.834342. eCollection 2022.
10
Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism.
Front Neurol. 2021 Jun 10;12:665136. doi: 10.3389/fneur.2021.665136. eCollection 2021.
本文引用的文献
1
Subcutaneous versus intravenous immunoglobulin in multifocal motor neuropathy: a randomized, single-blinded cross-over trial.
Eur J Neurol. 2009 May;16(5):631-8. doi: 10.1111/j.1468-1331.2009.02568.x. Epub 2009 Feb 19.
2
Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.
Lancet Neurol. 2008 Oct;7(10):939-50. doi: 10.1016/S1474-4422(08)70215-1.
3
C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome.
J Peripher Nerv Syst. 2008 Sep;13(3):228-35. doi: 10.1111/j.1529-8027.2008.00181.x.
4
The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain-Barré syndrome.
J Neuroimmunol. 2008 Sep 15;201-202:172-82. doi: 10.1016/j.jneuroim.2008.05.028. Epub 2008 Jul 29.
5
Anti-inflammatory actions of intravenous immunoglobulin.
Annu Rev Immunol. 2008;26:513-33. doi: 10.1146/annurev.immunol.26.021607.090232.
6
Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model.
Brain. 2008 May;131(Pt 5):1197-208. doi: 10.1093/brain/awm316. Epub 2008 Jan 8.
7
Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial.
Lancet Neurol. 2008 Feb;7(2):136-44. doi: 10.1016/S1474-4422(07)70329-0.
8
Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy.
Muscle Nerve. 2008 Mar;37(3):406-9. doi: 10.1002/mus.20909.
9
The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model.
Int Immunol. 2007 Jul;19(7):857-65. doi: 10.1093/intimm/dxm052. Epub 2007 Jun 18.
10
Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity.
Proc Natl Acad Sci U S A. 2007 May 15;104(20):8433-7. doi: 10.1073/pnas.0702936104. Epub 2007 May 7.
Zotero 插件